View in EDS HTML Full Text PDF Full Text

Actionable loss of SLF2 drives B-cell lymphomagenesis and impairs the DNA damage response.

Saved in:
Bibliographic Details
Title: Actionable loss of SLF2 drives B-cell lymphomagenesis and impairs the DNA damage response.
Authors: Zhang L; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany., Wirth M; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Patra U; Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany., Stroh J; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany., Isaakidis K; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Rieger L; Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), Technische Universität München, Munich, Germany., Kossatz S; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Center for Translational Cancer Research (TranslaTUM), Technische Universität München, Munich, Germany.; Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany., Milanovic M; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Zang C; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Demel U; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.; Clinician Scientist Program, Berlin Institute of Health (BIH), Berlin, Germany., Keiten-Schmitz J; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany., Wagner K; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany., Steiger K; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Comparative Experimental Pathology, Institute of Pathology, Technical University of Munich, Munich, Germany., Rad R; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Center for Translational Cancer Research (TranslaTUM), Technische Universität München, Munich, Germany.; Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technische Universität München, Munich, Germany., Bassermann F; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), Technische Universität München, Munich, Germany., Müller S; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany., Keller U; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Schick M; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.
Source: EMBO molecular medicine [EMBO Mol Med] 2023 Sep 11; Vol. 15 (9), pp. e16431. Date of Electronic Publication: 2023 Jul 24.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: EMBO Press Country of Publication: Germany NLM ID: 101487380 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1757-4684 (Electronic) Linking ISSN: 17574676 NLM ISO Abbreviation: EMBO Mol Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37485814
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Actionable loss of SLF2 drives B-cell lymphomagenesis and impairs the DNA damage response.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Zhang+L%22">Zhang L</searchLink>; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Wirth+M%22">Wirth M</searchLink>; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Patra+U%22">Patra U</searchLink>; Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany.<br /><searchLink fieldCode="AU" term="%22Stroh+J%22">Stroh J</searchLink>; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Isaakidis+K%22">Isaakidis K</searchLink>; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Rieger+L%22">Rieger L</searchLink>; Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), Technische Universität München, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Kossatz+S%22">Kossatz S</searchLink>; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Center for Translational Cancer Research (TranslaTUM), Technische Universität München, Munich, Germany.; Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Milanovic+M%22">Milanovic M</searchLink>; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Zang+C%22">Zang C</searchLink>; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Demel+U%22">Demel U</searchLink>; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.; Clinician Scientist Program, Berlin Institute of Health (BIH), Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Keiten-Schmitz+J%22">Keiten-Schmitz J</searchLink>; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany.<br /><searchLink fieldCode="AU" term="%22Wagner+K%22">Wagner K</searchLink>; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany.<br /><searchLink fieldCode="AU" term="%22Steiger+K%22">Steiger K</searchLink>; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Comparative Experimental Pathology, Institute of Pathology, Technical University of Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Rad+R%22">Rad R</searchLink>; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Center for Translational Cancer Research (TranslaTUM), Technische Universität München, Munich, Germany.; Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technische Universität München, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Bassermann+F%22">Bassermann F</searchLink>; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), Technische Universität München, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Müller+S%22">Müller S</searchLink>; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany.<br /><searchLink fieldCode="AU" term="%22Keller+U%22">Keller U</searchLink>; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Schick+M%22">Schick M</searchLink>; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101487380%22">EMBO molecular medicine</searchLink> [EMBO Mol Med] 2023 Sep 11; Vol. 15 (9), pp. e16431. <i>Date of Electronic Publication: </i>2023 Jul 24.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22EMBO+Press%22">EMBO Press </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>101487380 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1757-4684 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217574676%22">17574676 </searchLink><i>NLM ISO Abbreviation: </i>EMBO Mol Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37485814
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.15252/emmm.202216431
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e16431
    Titles:
      – TitleFull: Actionable loss of SLF2 drives B-cell lymphomagenesis and impairs the DNA damage response.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zhang L
      – PersonEntity:
          Name:
            NameFull: Wirth M
      – PersonEntity:
          Name:
            NameFull: Patra U
      – PersonEntity:
          Name:
            NameFull: Stroh J
      – PersonEntity:
          Name:
            NameFull: Isaakidis K
      – PersonEntity:
          Name:
            NameFull: Rieger L
      – PersonEntity:
          Name:
            NameFull: Kossatz S
      – PersonEntity:
          Name:
            NameFull: Milanovic M
      – PersonEntity:
          Name:
            NameFull: Zang C
      – PersonEntity:
          Name:
            NameFull: Demel U
      – PersonEntity:
          Name:
            NameFull: Keiten-Schmitz J
      – PersonEntity:
          Name:
            NameFull: Wagner K
      – PersonEntity:
          Name:
            NameFull: Steiger K
      – PersonEntity:
          Name:
            NameFull: Rad R
      – PersonEntity:
          Name:
            NameFull: Bassermann F
      – PersonEntity:
          Name:
            NameFull: Müller S
      – PersonEntity:
          Name:
            NameFull: Keller U
      – PersonEntity:
          Name:
            NameFull: Schick M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 11
              M: 09
              Text: 2023 Sep 11
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1757-4684
          Numbering:
            – Type: volume
              Value: 15
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: EMBO molecular medicine
              Type: main
ResultId 1